Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines * Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for metastatic disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Bilirubin \< 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 times ULN) * Alanine aminotransferase (ALT) \< 2.5 times ULN * Serum creatinine =\< 1.5 mg/dL * Serum albumin \>= 3.0 g/dL * Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose * Patients with history of previously treated malignancies who have no evidence of disease for last five years are allowed to participate Exclusion Criteria: * Patients who are pregnant or lactating * Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =\< 3 weeks prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1 day 1 * Major surgery within four weeks before cycle 1 day 1 * Unstable cardiovascular function: * Symptomatic ischemia, or * Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular \[AV\] block or asymptomatic left anterior fascicular block \[LAFB\]/right bundle branch block \[RBBB\] will not be excluded), or * Congestive heart failure (CHF) of New York Heart Association (NYHA) class \>= 3, or * Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose * Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose * Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents * Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus \[HBV\] surface antigen) * Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months * Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea * Grade \>= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1 * History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1 * Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity based on physician's assessment * Serious psychiatric or medical conditions that could interfere with treatment * Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1 * Concurrent therapy with approved or investigational anticancer therapeutic * Presence of clinically significant ascites